Neurocrine Biosciences Inc (NBIX) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Neurocrine Biosciences Inc.
| Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|
| 20 | $163 | $98 | $122.35 | $100.52 | 21.72% |
The Trend in the Analyst Price Target
Over the past 85 days, NBIX's average price target has gone down $6.13.
NBIX reports an average of 23.94% for its upside potential over the past 12 months.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-06-13 | 20 | 163 | 98 | 122.35 | 98.61 | 24.07% |
| 2021-06-05 | 20 | 163 | 98 | 122.35 | 94.39 | 29.62% |
| 2021-05-22 | 20 | 163 | 98 | 122.35 | 95.97 | 27.49% |
| 2021-05-15 | 20 | 163 | 98 | 122.95 | 94.60 | 29.97% |
| 2021-05-08 | 20 | 163 | 98 | 124.00 | 91.04 | 36.2% |
| 2021-04-25 | 21 | 163 | 101 | 126.86 | 96.73 | 31.15% |
| 2021-04-17 | 21 | 163 | 101 | 127.10 | 96.58 | 31.6% |
| 2021-04-10 | 21 | 163 | 101 | 128.05 | 93.35 | 37.17% |
| 2021-04-03 | 21 | 163 | 101 | 128.48 | 98.18 | 30.86% |
| 2021-03-20 | 21 | 163 | 101 | 128.48 | 92.22 | 39.32% |
| 2021-03-13 | 21 | 163 | 101 | 128.48 | 97.06 | 32.37% |
| 2021-03-06 | 21 | 163 | 101 | 128.48 | 93.23 | 37.81% |
| 2021-02-27 | 21 | 163 | 105 | 129.00 | 109.51 | 17.8% |
| 2021-02-20 | 21 | 163 | 105 | 129.00 | 113.24 | 13.92% |
| 2021-02-13 | 21 | 163 | 105 | 129.00 | 114.10 | 13.06% |
| 2021-02-06 | 21 | 163 | 105 | 129.00 | 116.14 | 11.07% |
| 2021-01-30 | 21 | 145 | 105 | 125.19 | 109.75 | 14.07% |
| 2021-01-23 | 21 | 145 | 90 | 124.48 | 116.91 | 6.48% |
| 2021-01-16 | 21 | 145 | 90 | 123.76 | 107.69 | 14.92% |
| 2021-01-09 | 21 | 145 | 90 | 123.76 | 112.07 | 10.43% |
| 2021-01-02 | 21 | 145 | 90 | 123.91 | 95.85 | 29.27% |
| 2020-12-26 | 21 | 161 | 90 | 125.48 | 97.67 | 28.47% |
| 2020-12-19 | 21 | 161 | 90 | 125.33 | 101.43 | 23.56% |
| 2020-12-09 | 21 | 161 | 90 | 126.05 | 91.97 | 37.06% |
| 2020-12-07 | 21 | 161 | 90 | 126.43 | 91.07 | 38.83% |
| 2020-11-10 | 22 | 161 | 90 | 125.75 | 87.58 | 43.58% |
| 2020-10-27 | 21 | 161 | 105 | 138.38 | 100.14 | 38.19% |
| 2020-09-28 | 21 | 161 | 120 | 140.29 | 97.40 | 44.03% |
| 2020-09-26 | 21 | 161 | 120 | 140.29 | 97.70 | 43.59% |
| 2020-09-08 | 21 | 161 | 120 | 140.29 | 109.77 | 27.8% |
| 2020-08-31 | 21 | 161 | 120 | 140.29 | 116.42 | 20.5% |
| 2020-08-04 | 21 | 161 | 120 | 140.29 | 120.16 | 16.75% |
| 2020-07-22 | 21 | 152 | 105 | 135.14 | 130.42 | 3.62% |
| 2020-07-15 | 21 | 152 | 101 | 132.48 | 135.15 | -1.98% |
| 2020-07-05 | 22 | 149 | 101 | 128.00 | 125.37 | 2.1% |
| 2020-07-04 | 23 | 149 | 101 | 127.48 | 125.37 | 1.68% |
| 2020-06-25 | 23 | 149 | 101 | 127.48 | 128.47 | -0.77% |
| 2020-06-17 | 23 | 147 | 101 | 126.39 | NA | NA% |
| 2020-06-08 | 23 | 147 | 101 | 124.39 | NA | NA% |
NBIX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.46 | 9 | 9 | 7 | 0 | 0 | 25 |
The Trend in the Broker Recommendations
NBIX's average broker recommendation rating worsened by 0.4 over the prior 16 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- Neurocrine Biosciences Inc's number of analysts covering the stock is higher than 93.67% of all US stocks.
- NBIX has a greater average analyst price target than 94.53% of Pharmaceutical Products stocks.
- Neurocrine Biosciences Inc's upside potential (average analyst target price relative to current price) is higher than 17.41% of Pharmaceutical Products stocks.
- NBIX has a lower variance in analysts' estimates than 21.49% of all US stocks.
In the Pharmaceutical Products industry, ABT, BMRN and BMY are the three stocks most similar to Neurocrine Biosciences Inc regarding the price target and analyst recommendation information presented here.
Is NBIX a Buy, Hold or Sell? See the POWR Ratings now!